Announced Fri, 18 Sept, 2026 · 11:52 IST
Haleos Labs subsidiary clears USFDA inspection with zero observations
HALEOSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.9%1-day move
₹1495.00
prior close
₹1497.70
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.1+0.1+0.1+1.8-0.9+1.3+0.7+0.0+0.3-0.6————
Up moveDown movePending
AI summary
Haleos Labs' material subsidiary Mahi Drugs Private Limited successfully completed a USFDA inspection at its API manufacturing facility in Parawada, Andhra Pradesh from Sept 15 to Sept 18, 2026, with zero Form 483 observations. This matches the outcome of the prior USFDA inspection in January 2025, reflecting continued strong regulatory compliance and quality standards.
Likely market impact
Positive for shareholders — clean USFDA clearance supports continued US market access and signals strong quality standards at the API facility.